Shared digital NHS prescribing record could avoid nearly 1 million annual drug errors
World Pharma News
by
1d ago
Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed, and saving up to 22 lives every year, suggests a modelling study, published online in BMJ Quality & Safety. The figures, which are based on the assumption that such a system could reduce medication errors by at least 10%, and by as much as 50%, could also save £millions for the NHS, say the researchers ..read more
Visit website
Global study could change how children with multiple sclerosis are treated
World Pharma News
by
1d ago
A ground-breaking study - the largest of its kind globally - has found children with multiple sclerosis (MS) have better outcomes if treated early and with the same high-efficacy therapies as adults. There are a limited number of therapies approved for children with MS, with only one considered to be of high-efficacy - meaning highly effective ..read more
Visit website
FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
World Pharma News
by
3d ago
The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle ..read more
Visit website
Reducing the side effects of breast and ovarian cancer treatment
World Pharma News
by
5d ago
Some anti-cancer treatments not only target tumour cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with Basel-based FoRx Therapeutics, has identified the mechanism of action of PARP inhibitors, used in particular for breast and ovarian cancer in patients carrying the BRCA gene mutation ..read more
Visit website
Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial
World Pharma News
by
5d ago
An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical trial led by the National Institutes of Health (NIH). Currently, there is no treatment for GAN and the disease is usually fatal by 30 years of age. Fourteen children with GAN, ages 6 to 14 years, were treated with gene transfer therapy at the NIH Clinical Center and then followed for about six years to assess safety ..read more
Visit website
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
World Pharma News
by
5d ago
Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time ..read more
Visit website
Bayer and Aignostics to collaborate on next generation precision oncology
World Pharma News
by
1w ago
Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world's leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights ..read more
Visit website
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
World Pharma News
by
2w ago
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism ..read more
Visit website
European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
World Pharma News
by
2w ago
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company's 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age ..read more
Visit website
Novel molecules from generative AI to Phase II
World Pharma News
by
2w ago
There are thousands of diseases worldwide with no cure or available treatments. Traditional drug discovery and development takes decades and billions of dollars and more than 90% of these drugs fail in clinical trials. The emergence of artificial intelligence (AI) holds promise for streamlining and improving the entire process. However, ushering in a new era of AI-driven drug discovery requires costly and lengthy validation in preclinical cell, tissue, and animal models and human clinical trials ..read more
Visit website

Follow World Pharma News on FeedSpot

Continue with Google
Continue with Apple
OR